Associated Genetic Biomarkers
BCL6 Amplification is present in 0.36% of AACR GENIE cases, with non-small cell lung carcinoma, head and neck squamous cell carcinoma, squamous cell carcinoma, ovarian neoplasm, and breast carcinoma having the greatest prevalence .
BCL6 Amplification serves as an inclusion eligibility criterion in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains BCL6 Amplification as an inclusion criterion, 1 is phase 2 (0 open).
Trials with BCL6 Amplification in the inclusion eligibility criteria most commonly target mature B-cell lymphoma/leukemia .
Significance of BCL6 Amplification in Diseases
Mature B-Cell Lymphoma/Leukemia +
BCL6 Amplification is an inclusion criterion in 1 clinical trial for mature B-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCL6 Amplification and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.